Roche Holding AG (RHHBF)

OTCMKTS · Delayed Price · Currency is USD
347.36
+12.05 (3.59%)
Sep 16, 2025, 1:13 PM EDT
3.59%
Market Cap281.78B
Revenue (ttm)79.83B
Net Income (ttm)11.86B
Shares Outn/a
EPS (ttm)14.77
PE Ratio23.77
Forward PE13.64
Dividend10.97 (3.11%)
Ex-Dividend DateMar 28, 2025
Volume21
Average Volume81
Open347.36
Previous Close335.30
Day's Range347.36 - 347.36
52-Week Range280.85 - 380.00
Beta0.18
RSI46.05
Earnings DateOct 20, 2025

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]

Sector Healthcare
Founded 1896
Employees 103,249
Stock Exchange OTCMKTS
Ticker Symbol RHHBF
Full Company Profile

Financial Performance

In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.

Financial numbers in CHF Financial Statements

News

Roche Holding Integrates Its Continuous Glucose Monitoring Solution With MySugr App

(RTTNews) - Roche Holding AG (RHHBY.PK), Tuesday announced the integration of Accu-Chek SmartGuide's AI-enabled predictive continuous glucose monitoring solution with the mySugr diabetes management ap...

7 hours ago - Nasdaq

Roche receives CE Mark for Accu-Chek SmartGuide Continuous Glucose Monitoring and mySugr App integration, offering an enhanced diabetes management experience

The integration of Accu-Chek SmartGuide's AI-enabled predictive CGM with the popular mySugr app delivers a simple, intuitive solution for people to manage their diabetes with greater ease. Accu-Chek S...

10 hours ago - PRNewsWire

The Zacks Analyst Blog Highlights Roche, Linde, Disney and Vaso

Zacks spotlights Roche, Linde, Disney, and Vaso as analysts weigh drug demand, gas contracts, global expansion, and IT-driven resilience.

15 hours ago - Nasdaq

Fosun’s Henlius in talks with Johnson & Johnson, Roche on cancer drug

Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms including Johnson & Johnson and Roche Holding about selling them the rights to an experimental cancer drug, people familiar...

16 hours ago - South China Morning Post

Henlius Biotech in talks with J&J, Roche on cancer drug: report

Shanghai Henlius may sell rights to cancer drug HLX43 to J&J or Roche, with a deal worth hundreds of millions.

20 hours ago - Seeking Alpha

Top Analyst Reports for Roche, Linde & Walt Disney

Roche gains from strong drug demand, Linde builds on record orders, while Disney faces TV woes and bets on global growth.

1 day ago - Nasdaq

Roche Holding AG (RHHBY) Presents at Goldman Sachs 22nd European Medtech & Healthcare Services Conference - Slideshow

The following slide deck was published by Roche Holding AG in conjunction with this event.

6 days ago - Seeking Alpha

Roche Holding AG (RHHBY) Gains CE-IVDR Approval for VENTANA HER2 (4B5) Test | RHHBY stock news

Roche Holding AG (RHHBY) Gains CE-IVDR Approval for VENTANA HER2 (4B5) Test | RHHBY stock news

11 days ago - GuruFocus

New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or ...

New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD) | RHHBY Stock News

11 days ago - GuruFocus

Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify ...

Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients | RHHBY Stock News

11 days ago - GuruFocus

Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients

The VENTANA HER2 (4B5) test is now CE-IVDR approved to aid in the assessment of HER2-ultralow status to identify metastatic breast cancer patients who may be eligible for treatment with ENHERTU. The V...

11 days ago - PRNewsWire

New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)

Basel, 05 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data from the AVONELLE-X and SALWEEN studies of Vabysmo® (faricimab),1,2 presented at the 25th Euretina Congress in Pa...

11 days ago - GlobeNewsWire

New Data for Genentech's Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data from the AVONELLE-X and SALWEEN studies of Vabysmo® (faricim...

11 days ago - Business Wire

Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)

Basel, 04 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received the EU CE mark for its Port Delivery Platform containing Susvimo, which will now be known as Contivue...

12 days ago - GlobeNewsWire

Global drugmakers rush to boost US presence as tariff threat looms

Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

13 days ago - Reuters

Three Dividend Funds with Foreign Flair

This month's trio includes an unofficial dividend aristocrat.

14 days ago - Morningstar

Alnylam (ALNY) Advances with Roche on Phase 3 Cardiovascular Trial for Zilebesiran

Alnylam (ALNY) Advances with Roche on Phase 3 Cardiovascular Trial for Zilebesiran

17 days ago - GuruFocus

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for ...

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension | RHHBY Stock News

17 days ago - GuruFocus

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardio...

17 days ago - Business Wire

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

Basel, 30 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardiovascular outcomes trial (CVOT) to evaluate the ability ...

17 days ago - GlobeNewsWire

Analog Devices Chair & CEO Trades $5.09M In Company Stock

It was reported on August 28, that VINCENT ROCHE , Chair & CEO at Analog Devices (NASDAQ: ADI) executed a significant insider sell, according to an SEC filing. What Happened: ROCHE's recent Form 4 fi...

18 days ago - Benzinga

Roche's US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA

Basel, 25 August 2025 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today broke ground on its newest US manufacturing site in Holly Springs, North Carolina. This significant d...

22 days ago - GlobeNewsWire

Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina

HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today broke ground on its newest U.S. manufacturing site in Holly Springs, North Carolina. Th...

22 days ago - Business Wire

“Walk in My Shoes” Spotlights the Invisible Struggles of People Living with Multiple Sclerosis (MS) – a Public Health Awareness Initiative by Roche in Collaboration with Multiple Sclerosis Society of India (MSSI)

Roche Pharma India, in collaboration with the Multiple Sclerosis Society of India (MSSI) presents Walk In My Shoes – a public health awareness initiative to highlight the often invisible struggles of ...

24 days ago - Business Upturn